drugset / Trial / NCT00568477
Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation
Phase 2
Terminated
200 enrolled
Technical University of Munich
Heidelberg University · collabHeinrich-Heine University, Duesseldorf · collabHumboldt-Universität zu Berlin · collabMartin-Luther-Universität Halle-Wittenberg · collabTransplantationszentrum Köln-Merheim · collabUniversity Hospital Freiburg · collabUniversity Hospital, Essen · collabUniversity of Erlangen-Nürnberg · collabUniversity of Jena · collabUniversity of Regensburg · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the benefit of rituximab in patients with CAN with histologically proven C4d deposits and/or plasma cell and/or B-Lymphocyte (CD20+ cells) infiltration of their grafts.
Timeline
- Start
- 2007-12
- Primary completion
- —
- Completion
- 2010-12
Outcome
Outcome not reported
Stopped (Enrollment): “lacking recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |